Characterization of oligomerization-aggregation products of neurodegenerative target proteins by ion mobility mass spectrometry

Methods in Molecular Biology

Volumn 896, Issue , 2012, Pages 399-412

  Vlad, Camelia ^a   Iurascu, Marius Ionut ^a   Slamnoiu, Stefan ^a   Hengerer, Bastian ^b   Przybylski, Michael ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Amyloid; Synuclein; Alzheimer's disease; Ion mobility mass spectrometry; Oligomerization; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; MASS SPECTROMETRY; METHODOLOGY; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY;

EID: 84865326718     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3704-8_27     Document Type: Article

References (40)

1. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, StefaniM(2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-511
2. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279:46363-46366
3. Morgan D (2006) Immunotherapy for Alzheimer's disease. J Alzheimers Dis 9:425-432
4. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci USA 103:1661-1668
5. GoedertM(2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501
6. Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103:17-37
7. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6:197-208
8. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804-2815
9. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822
10. Tolnay M, Probst A (1999) Review: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 25:171-187
11. Johnson RT, Gibbs CJ (1998) Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 339:1994-2004
12. Horiuchi M, Caughey B (1999) Prion protein interconversions and the transmissible spongiform encephalopathies. Structure (London, England) 7:231-240
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
14. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, RiessO(1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
15. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173
16. Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH et al (2004) Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 117:1017-1024
17. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87:181-194
18. Crews L, Tsigelny I, Hashimoto M, Masliah E (2009) Role of synucleins in Alzheimer's disease. Neurotox Res 16:306-317
19. Hull M, Berger M, Heneka M (2006) Diseasemodifying therapies in Alzheimer's disease: how far have we come? Drugs 66:2075-2093
20. Heck AJ, Van Den Heuvel RH (2004) Investigation of intact protein complexes by mass spectrometry. Mass Spectrom Rev 23:368-389
21. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64-71
22. Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M, Marcus K (2006) Proteomics in neurodegeneration-disease driven approaches. J Neural Transm 113:1055-1073
23. Mann M, Hendrickson RC, Pandey A (2001) Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 70:437-473
24. Perdivara I, Petrovich R, Allinquant B, Deterding LJ, Tomer KB, Przybylski M (2009) Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography-mass spectrometry using electron transfer dissociation and collision induced dissociation. J Proteome Res 8:631-642
25. Perdivara I, Deterding L, Moise A, Tomer KB, PrzybylskiM(2008) Determination of primary structure and microheterogeneity of a betaamyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry. Anal Bioanal Chem 391:325-336
26. Przybylski M, Glocker MO (1996) Electrospray mass spectrometry of biomacromolecular complexes with noncovalent interactions-new analytical perspectives for supramolecular chemistry and molecular recognition processes. Angew Chem Int Ed Engl 35:806-826
27. Kebarle P, Verkerk UH (2009) Electrospray: from ions in solution to ions in the gas phase, what we know now. Mass Spectrom Rev 28:898-917
28. Nemes P, Goyal S, Vertes A (2007) Conformational and noncovalent complexation changes in proteins during electrospray ionization. Anal Chem 80:387-395
29. Ruotolo BT, Benesch JL, Sandercock AM, Hyung SJ, Robinson CV (2008) Ion mobility-mass spectrometry analysis of large protein complexes. Nat Protoc 3:1139-1152
30. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT (2009) Amyloid-ß protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's Disease. Nat Chem 1:326-331
31. Thalassinos K, Slade SE, Jennings KR, Scrivens JH, Giles K, Wildgoose J, Hoyes J, Bateman RH, Bowers MT (2004) Ion mobility mass spectrometry of proteins in a modified commercial mass spectrometer. Int J Mass Spectrom 236:55-63
32. Bleiholder C, Dupuis NF, Wyttenbach T, Bowers MT (2011) Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to ß-sheet in amyloid fibril formation. Nat Chem 3:172-177
33. Ruotolo BT, Hyung SJ, Robinson PM, Giles K, Bateman RH, Robinson CV (2007) Ion mobility-mass spectrometry reveals long-lived, unfolded intermediates in the dissociation of protein complexes. Angew Chem Int Ed Engl 46:8001-8004
34. Trimpin S, Clemmer DE (2008) Ion mobility spectrometry/mass spectrometry snapshots for assessing the molecular compositions of complex polymeric systems. Anal Chem 80:9073-9083
35. Kanu AB, Dwivedi P, TamM, Matz L, HillHH Jr (2008) Ion mobility-mass spectrometry. J Mass Spectrom 43:1-22
36. Henderson SC, Valentine SJ, Counterman AE, Clemmer DE (1999) ESI/ion trap/ion mobility/time-of-flight mass spectrometry for rapid and sensitive analysis of biomolecular mixtures. Anal Chem 71:291-301
37. Zhou M, Sandercock AM, Fraser CS, Ridlova G, Stephens E, Schenauer MR, Yokoi-Fong T, Barsky D, Leary JA, Hershey JW et al (2008) Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc Natl Acad Sci USA 105:18139-18144
38. Iurascu MI, Cozma C, Tomczyk N, Rontree J, Desor M, Drescher M, Przybylski M (2009) Structural characterization of beta-amyloid oligomer-aggregates by ion mobility mass spectrometry and electron spin resonance spectroscopy. Anal Bioanal Chem 395:2509-2519
39. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220-9232
40. Vlad C, Lindner K, Karreman C, Schildknecht S, Leist M, Tomczyk N, Rontree J, Langridge J, Danzer K, Ciossek T, Petre A, Gross ML, Hengerer B, PrzybylskiM(2011) Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry. Chem Bio Chem 12:2740-2744